NA
AMAG

Navellier & Associates’s AMAG Pharmaceuticals AMAG Stock Holding History

Navellier & Associates’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-25,615
Closed -$1.02M – 321
2015
Q3 		$1.02M Sell
25,615
-226
-0.9% -$14K 0.1% 89
2015
Q2 		$1.78M Buy
25,841
+17,941
+227% +$1.13M 0.16% 78
2015
Q1 		$432K Buy
+7,900
New +$377K 0.04% 226

Other funds holding AMAG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Navellier & Associates's AMAG Position: Q4 2015 in Review

Navellier & Associates sold out of AMAG Pharmaceuticals (AMAG) in Q4 2015, closing a stake of 25,615 shares — an estimated $1.02M sold.

Navellier & Associates first reported a position in AMAG in Q1 2015 and held it in 3 quarters. The position peaked at $1.78M in Q2 2015. 172 funds tracked by Wall St. Rank hold AMAG as of Q4 2015.

  • Navellier & Associates reported no remaining AMAG Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Navellier & Associates sold 25,615 AMAG Pharmaceuticals shares in Q4 2015, an estimated $1.02M.
  • Navellier & Associates first reported a position in AMAG Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • Navellier & Associates's AMAG Pharmaceuticals position peaked at $1.78M in Q2 2015.
  • 172 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2015.

Based on Navellier & Associates's 13F filing for Q4 2015, filed 10 Feb 2016.